智通财经网·2025-12-15 10:19Core Viewpoint - Fosun Pharma plans to invest a total of 1.412 billion yuan to acquire a controlling stake in Green Valley Pharmaceutical, focusing on clinical research and daily operations [1][2]. Group 1: Investment Details - Fosun Pharma's subsidiary intends to invest 143 million yuan to acquire 20.15 million yuan of registered capital from the current shareholders [1]. - The subsidiary will also contribute 1.269 billion yuan to subscribe for 201 million yuan of new registered capital [1]. - The acquisition involves a phased transfer of 8.667347 million yuan of registered capital to a special purpose vehicle (SPV) jointly established by Fosun Pharma and the founders [1]. Group 2: Product Information - The target group's product, Manzoudexan Capsules, is a treatment for mild to moderate Alzheimer's disease, showing significant cognitive improvement in patients, especially those with moderate conditions [2]. - Following the acquisition, the group will continue to advance post-marketing confirmatory clinical trials for the drug to expedite approval from national drug regulatory authorities [2]. - The group plans to initiate international multi-center clinical studies for related indications to benefit more Alzheimer's patients [2].